Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Eligard After Radical Prostatectomy in High-Risk Prostate Cancer
NCT01442246Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jul 2011
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in prostate adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Metastasis-Free Survival at 10 years. Started Jul 2011; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT01442246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442246.